Mga Batayang Estadistika
| CIK | 1505065 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BrainsWay Ltd. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
Exhibit 99.1 BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd. This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device is pending Premarket Approval from the U.S. FDA, a |
|
| August 21, 2025 |
Exhibit 99.4 - 1 - THE COMPANIES LAW, 5759-1999 A PRIVATE COMPANY LIMITED BY SHARES Amended and Restated Articles of Association of Neurolief LTD. General 1. 1.1. The name of the Company is “Neurolief Ltd.”. 1.2. The object of the Company is to engage in any lawful activity or business. 1.3. The liability of each Shareholder is limited to the unpaid portion of the par value of each share held by s |
|
| August 21, 2025 |
Exhibit 99.3 CALL OPTION AGREEMENT THIS CALL OPTION AGREEMENT (the “Agreement”) is made and entered into this 18th day of August, 2025 by and among BrainsWay Ltd., an Israeli public company (the “Buyer” or the “Investor”), Neurolief Ltd., a company organized under the laws of the State of Israel (the “Company”), and the persons listed in Schedule A hereto, as may be amended and/or supplemented fro |
|
| August 21, 2025 |
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 99.5 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 18th day of August 2025, by and among Neurolief Ltd., an Israeli company (the “Company”), BrainsWay Ltd., an Israeli company (“BWAY”) and certain holders of Preferred Shares listed on Schedule A hereto (the “Investors”) and signatory |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+972 |
|
| August 21, 2025 |
Exhibit 99.2 INVESTMENT AGREEMENT THIS INVESTMENT AGREEMENT (the “Agreement”) is made and entered into effective as of the 18th day of August, 2025, by and among Neurolief Ltd., a company organized under the laws of the State of Israel having its principal offices at 12 Giborei Israel, Netanya, Israel, 4250412 (the “Company”) and Brainsway Ltd., a company organized under the laws of the State of I |
|
| August 20, 2025 |
EXHIBIT 99.1 BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health The Investment is part of BrainsWay’s ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or th |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+97 |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+97 |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+97 |
|
| August 13, 2025 |
EXHIBIT 99.1 BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Co |
|
| August 13, 2025 |
Exhibit 99.1 A New Era in Brain Disorder Treatment Corporate Presentation Nasdaq/TASE: BWAY August 2025 Disclaimer Safe Harbor and Non - GAAP/IFRS Financial Measures This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company’s securities or to participate in any investment in the Company . This prese |
|
| August 6, 2025 |
Notice to Owners of Ordinary Shares Exhibit 99.2 Notice to Owners of Ordinary Shares Brainsway Ltd. Proxy Card Owners of record on August 12, 2025 (the “Record Date”) of Ordinary Shares of Brainsway Ltd. (the “Company”) are hereby notified of an upcoming annual general meeting of the Company to be held on Thursday, September 11, 2025, in Israel (the “Annual Meeting”). Shareholders registered in the Company’s shareholders register in |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant’s name into English) 16 Hartum Street, RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (Ad |
|
| August 6, 2025 |
Exhibit 99.1 BRAINSWAY LTD. 16 Hartum Street, RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516 Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on September 11, 2025 The Annual General Meeting of Shareholders of BrainsWay Ltd. (the “Company”), will be held at the offices of the Company, 16 Hartum Street, RAD Tower, 14th Floor, Har HaHotzvim, Jerusalem, Israel on September 1 |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+972- |
|
| June 11, 2025 |
EXHIBIT 99.1 BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD) Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial BURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader i |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+972- |
|
| June 4, 2025 |
EXHIBIT 99.1 BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, June 04, 2025 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader i |
|
| May 13, 2025 |
6-K 1 f6k051225.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerus |
|
| May 13, 2025 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a record net numb |
|
| May 1, 2025 |
Up to 3,603,745 American Depositary Shares representing 7,207,490 Ordinary Shares BRAINSWAY LTD. Filed Pursuant to Rule 424(b)(3) Registration No. 333-286672 PROSPECTUS Up to 3,603,745 American Depositary Shares representing 7,207,490 Ordinary Shares BRAINSWAY LTD. This prospectus relates to the offer and sale from time to time by the selling shareholder named in this prospectus of up to an aggregate of 3,603,745 of our American Depositary Shares (the “Offered ADSs”), with each American Depos |
|
| April 28, 2025 |
Brainsway Ltd. 16 Hartum Street, RAD Tower, 14th Floor Har HaHotzvim Jersusalem, 9777516, Israel Brainsway Ltd. 16 Hartum Street, RAD Tower, 14th Floor Har HaHotzvim Jersusalem, 9777516, Israel April 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services Washington, D.C. 20549 Attention: Nicholas O’Leary Re: Brainsway Ltd. Registration Statement on Form F-3 Filed on April 22, 2025 File No. 333-286672 (the “Regi |
|
| April 22, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements: (1) Registration Statement (Form F-3 No. 333-280934) of Brainsway Ltd. and in the related Prospectus, (2) Registration Statement (Form S-8 No. 333-230979) pertaining to the 2014 Share Incentive Plan of Brainsway Ltd. of our reports dated April 21, 2025, |
|
| April 22, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Brainsway Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| April 22, 2025 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Hadar Levy, certify that: 1. I have reviewed this annual report on Form 20-F of BrainsWay Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circum |
|
| April 22, 2025 |
Exhibit 13 CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of BrainsWay Ltd. |
|
| April 22, 2025 |
As filed with the Securities and Exchange Commission on April 22, 2025 As filed with the Securities and Exchange Commission on April 22, 2025 Registration No. |
|
| April 22, 2025 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ido Marom, certify that: 1. I have reviewed this annual report on Form 20-F of BrainsWay Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circums |
|
| April 22, 2025 |
Brainsway Ltd. Insider Trading Compliance Policy Exhibit 11.1 Brainsway Ltd. Insider Trading Compliance Policy This Insider Trading Compliance Policy (this “Policy”) consists of five sections: · Section I provides an overview; · Section II sets forth the policies of the Company prohibiting insider trading; · Section III explains insider trading; · Section IV consists of procedures that have been put in place by the Company to prevent insider tra |
|
| April 22, 2025 |
Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL The following description of our share capital is a summary of the rights of our ordinary shares and certain provisions of our articles of association currently in effect. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of association previously filed with the Securities and Exchange Commission |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 11, 2025 |
EXHIBIT 99.1 BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+972 |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+ |
|
| December 12, 2024 |
EXHIBIT 99.1 BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third |
|
| November 20, 2024 |
EXHIBIT 99.1 BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy Reductions also seen in comorbid anxiety and depression symptoms BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health dis |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+ |
|
| November 14, 2024 |
SC 13G/A 1 zk2432339.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) Brainsway Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106 (CUSIP Number) October 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 14, 2024 |
SC 13G/A 1 zk2432338.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) Brainsway Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| November 13, 2024 |
SC 13D 1 ea0220999-13dvalorbrain.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BrainsWay Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share American Depository Shares, each representing two Ordinary Shares (Title of Class of Securities) 10501L106(1) (CUSIP Number(s)) |
|
| November 13, 2024 |
EX-99.6 2 ea022099901ex99-6brain.htm JOINT FILING AGREEMENT DATED AS OF NOVEMBER 13, 2024 AMONG THE REPORTING PERSONS Exhibit 99.6 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned does hereby consent and agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and all amendme |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+ |
|
| November 12, 2024 |
EXHIBIT 99.1 BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) |
|
| November 5, 2024 |
FIRST AMENDMENT TO Registration Rights Agreement Exhibit 99.2 FIRST AMENDMENT TO Registration Rights Agreement This First Amendment (this “Amendment”) to the Registration Rights Agreement (as defined below) is made and entered into as of November 5, 2024, by and between BrainsWay Ltd., a company organized under the laws of Israel (the “Company”) and Valor BrainsWay Holdings, LLC (the “Investor”). Capitalized terms used but not defined herein sha |
|
| November 5, 2024 |
Results of Extraordinary General Shareholder Meeting Exhibit 99.1 Results of Extraordinary General Shareholder Meeting At the Extraordinary General Meeting of Shareholders of BrainsWay Ltd. (the “Company”) held on November 5, 2024, the proposed resolution was approved by the required majority of the shareholders. Below is the proposal which was adopted, as well as the share of support that the resolution received: (1) Resolved, that the following ma |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File No.: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+972-2) |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+9 |
|
| October 9, 2024 |
EXHIBIT 99.1 BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expa |
|
| October 1, 2024 |
Exhibit 99.1 BRAINSWAY LTD. 16 Hartum Street, RAD Tower, 14th Floor Har HaHotzvim, Jerusalem 9777516 Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on November 5, 2024 The Extraordinary General Meeting of Shareholders of BrainsWay Ltd. (the “Company”), will be held at the offices of the Company, 16 Hartum Street, RAD Tower, 14th Fl, Har HaHotzvim, Jerusalem, Israel on No |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+9 |
|
| October 1, 2024 |
Notice to Owners of Ordinary Shares Brainsway Ltd. Proxy Card Exhibit 99.2 Notice to Owners of Ordinary Shares Brainsway Ltd. Proxy Card Owners of record on October 8, 2024 (the “Record Date”) of Ordinary Shares of Brainsway Ltd. (the “Company”) are hereby notified of an upcoming extraordinary general meeting of the Company to be held on November 5, 2024 in Israel (the “Extraordinary Meeting”). Shareholders registered in the Company’s shareholders register i |
|
| September 30, 2024 |
EXHIBIT 99.4 Registration Rights Agreement This Registration Rights Agreement (this “Agreement”) is entered into as of September 29, 2024, by and among BrainsWay Ltd, a company organized under the laws of Israel (the “Company”), and the investor listed on the signature page(s) hereto (the “Investor”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective mea |
|
| September 30, 2024 |
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BRAINSWAY LTD EXHIBIT 99.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 30, 2024 |
EXHIBIT 99.1 BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners Company to leverage capital and Valor’s expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™ Purchase price of US$9.51 represents a 20% premium over 30-day VWAP of BrainsWay’s American Depositary Shares Valor provides growt |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Isra |
|
| September 30, 2024 |
EXHIBIT 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 29, 2024, between BrainsWay Ltd, a company organized under the laws of Israel (the “Company”), and Valor BrainsWay Holdings, LLC (such entity, including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pu |
|
| September 16, 2024 |
EXHIBIT 99.1 BrainsWay Announces Significant Expansion on U.S. East Coast 14 Deep TMS™ Devices Ordered by Large Mental Health Network BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the expansion of |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Isra |
|
| September 10, 2024 |
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals EXHIBIT 99.1 Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the Israel Ministry of Defe |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Isra |
|
| August 29, 2024 |
EXHIBIT 99.1 BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorde |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| August 6, 2024 |
EXHIBIT 99.1 BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Fourth Consecutive Quarter Raising Lower End of Full-Year 2024 Revenue Guidance to Range of $38.5 Million to |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| August 5, 2024 |
Brainsway Ltd. 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel Brainsway Ltd. 16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel August 5, 2024 By EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 RE: Brainsway Ltd. Registration Statement on Form F-3 Filed July 22, 2024 File No. 333-280934 Ladies and Gentlemen: Pursuant to Rules 460 and 461 of th |
|
| July 22, 2024 |
As filed with the Securities and Exchange Commission on July 22, 2024 As filed with the Securities and Exchange Commission on July 22, 2024 Registration No. |
|
| July 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Brainsway Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File No.: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (+972-2) |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (A |
|
| June 17, 2024 |
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada EXHIBIT 99.1 BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced its broad market entry into Canada for the Comp |
|
| June 10, 2024 |
EXHIBIT 99.1 BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™ BURLINGTON, Mass. and JERUSALEM, June 10, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasiv |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (A |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (A |
|
| June 3, 2024 |
EXHIBIT 99.1 BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Treatment in Patients Between the Ages of 68 and 86 BURLINGTON, Mass. and JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation |
|
| May 9, 2024 |
Exhibit 99.1 BRAINSWAY LTD. 19 Hartum Street, Bynet Building, 3rd Floor Har HaHotzvim, Jerusalem 9777518 Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on June 17, 2024 The Annual General Meeting of Shareholders of BrainsWay Ltd. (the “Company”), will be held at the offices of the Company, 19 Hartum Street, Bynet Building, 3rd Fl, Har HaHotzvim, Jerusalem, Israel on June 17, 20 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| May 9, 2024 |
Notice to Owners of Ordinary Shares Brainsway Ltd. Proxy Card Exhibit 99.2 Notice to Owners of Ordinary Shares Brainsway Ltd. Proxy Card Owners of record on May 8, 2024 (the “Record Date”) of Ordinary Shares of Brainsway Ltd. (the “Company”) are hereby notified of an upcoming annual general meeting of the Company to be held on Monday June 17, 2024 in Israel (the “Annual Meeting”). Shareholders registered in the Company's shareholders register in Israel and s |
|
| May 8, 2024 |
EXHIBIT 99.1 BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Third Consecutive Quarter Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| April 17, 2024 |
EXHIBIT 99.1 BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates Company Announces 11th Recent System Installed in Israel, with More Expected this Year BURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen |
|
| April 4, 2024 |
EXHIBIT 99.1 BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms JERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostim |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| March 28, 2024 |
BRAINSWAY LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 BRAINSWAY LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION BrainsWay LTD. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 112. 1. Persons Subject to Policy This Policy |
|
| March 28, 2024 |
Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL The following description of the capital stock of BrainsWay is a summary of the rights of our ordinary shares and certain provisions of our articles of association currently in effect. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of association previously filed with the Securities and Exchan |
|
| March 28, 2024 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Hadar Levy, certify that: 1. I have reviewed this annual report on Form 20-F of BrainsWay Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circum |
|
| March 28, 2024 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ido Marom, certify that: 1. I have reviewed this annual report on Form 20-F of BrainsWay Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circums |
|
| March 28, 2024 |
Exhibit 13 CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of BrainsWay Ltd. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 28, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form F-3 No. 333- 259610) of BrainsWay Ltd. and in the related Prospectus of our report dated March 28, 2024, with respect to the consolidated financial statements of BrainsWay Ltd. included in this Annual Report (Form 20-F) for the year ended December 3 |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| March 18, 2024 |
EXHIBIT 99.1 BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems Katie’s Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families BURLINGTON, Mass. and JERUSALEM, March 18, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in |
|
| March 6, 2024 |
EXHIBIT 99.1 BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights Generated Record Revenues with Robust 50% Year-over-Year Revenue Growth in Q4 2023; Generated Positive Quarterly Net Income Providing Full-Year 2024 Revenue Guidance of $37-$40 Million with Continued Profitability Momentum and Cash Generation Conference Call to be Held Today at 8:30 AM ET |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| February 21, 2024 |
BWAY / BrainsWay Ltd. - Depositary Receipt (Common Stock) / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 BrainsWay Ltd. (Name of Issuer) American Depositary Shares each representing two Ordinary Shares (Title of Class of Securities) 10501L106 (CUSIP Number) February 13, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* BrainsWay Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106** (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| February 7, 2024 |
BWAY / BrainsWay Ltd. - Depositary Receipt (Common Stock) / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 BrainsWay Ltd. (Name of Issuer) American Depositary Shares each representing two Ordinary Shares (Title of Class of Securities) 10501L106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| January 10, 2024 |
BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology EXHIBIT 99.1 BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will be clinically evaluating an innovative |
|
| December 19, 2023 |
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network EXHIBIT 99.1 BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced increased collaboration with a growing mental health treat |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| November 20, 2023 |
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives EXHIBIT 99.1 Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Blue Cross Blue Shield of Louisiana (BCBS of LA) has joined t |
|
| November 15, 2023 |
EXHIBIT 99.1 BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights Generated Robust 61% Year-over-Year Revenue Growth in Q3 2023 Nearing Breakeven Operating Income, Achieved Positive Adjusted EBITDA, with Cash Flow from Operations Exceeding $1 Million Conference Call to be Held Today at 8:30 AM EST BURLINGTON, Mass. and JERUSALEM, Nov. 15, 2023 (GLOBE NEWSWIRE) - Brains |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| November 2, 2023 |
EXHIBIT 99.1 Clinical TMS Society Publishes First Coverage Recommendations for the Treatment of Smoking Addiction BrainsWay Deep TMS™ is the Only TMS System FDA-Cleared to Treat Smoking Addiction BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments f |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| October 16, 2023 |
EXHIBIT 99.1 BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Protocols BURLINGTON, Mass. and JERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in adv |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Isra |
|
| September 20, 2023 |
EXHIBIT 99.1 BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie’s Way Plus Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced |
|
| September 5, 2023 |
EXHIBIT 99.1 BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S. 10 Deep TMS™ Systems to be Installed in 2023 Alone BURLINGTON, Mass. and JERUSALEM, Sept. 05, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments, today announced the formation of a strategic part |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Isra |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| August 23, 2023 |
EXHIBIT 99.1 BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan BURLINGTON, Mass. and JERUSALEM, Aug. 23, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health dis |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| August 9, 2023 |
BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights EXHIBIT 99.1 BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights BURLINGTON, Mass. and JERUSALEM, Aug. 09, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported second quarter 2023 financial results and provided an operational update. Recen |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (A |
|
| July 11, 2023 |
EXHIBIT 99.1 BrainsWay Accelerates International Expansion in India Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™ BURLINGTON, Mass. and JERUSALEM, July 11, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (A |
|
| June 21, 2023 |
EXHIBIT 99.1 BrainsWay Announces Significant Expansion in Western and Central U.S. 30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS Network BURLINGTON, Mass. and JERUSALEM, June 21, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announc |
|
| June 14, 2023 |
BWAY / Brainsway Ltd - ADR / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BrainsWay Ltd. (Name of Issuer) American Depositary Shares each representing two Ordinary Shares (Title of Class of Securities) 10501L106 (CUSIP Number) June 7, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| May 23, 2023 |
BrainsWay Announces Appointment of Ido Marom as CFO EXHIBIT 99.1 BrainsWay Announces Appointment of Ido Marom as CFO BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industrie |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| May 17, 2023 |
BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights EXHIBIT 99.1 BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quarter 2023 financial results and provided an operational update. Recent F |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| April 3, 2023 |
BWAY / Brainsway Ltd - ADR / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) Brainsway Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 27, 2023 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Hadar Levy, certify that: 1. I have reviewed this annual report on Form 20-F of BrainsWay Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circum |
|
| March 27, 2023 |
Exhibit 13 CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of BrainsWay Ltd. |
|
| March 27, 2023 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, R. Scott Areglado, certify that: 1. I have reviewed this annual report on Form 20-F of BrainsWay Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 27, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form F-3 No. 333- 259610) of BrainsWay Ltd. and in the related Prospectus of our report dated March 27, 2023, with respect to the consolidated financial statements of BrainsWay Ltd. included in this Annual Report (Form 20-F) for the year ended December 3 |
|
| March 27, 2023 |
Exhibit 4.3 BrainsWay Ltd. (The "Company") Compensation Policy (the “Policy” or “Compensation Policy”) As adopted by the Company's Shareholders on December 22, 2021 as amended March 20, 2023. 1. Definitions “Board” - The Company's board of directors; "Committee" - The Company's compensation committee; "Company" - BrainsWay Ltd.; "Companies Law" - The Companies Law, 1999, Israel; "Director" - The m |
|
| March 27, 2023 |
Amendment to Employment Agreement BrainsWay and Hadar Levy Exhibit 4.6 Amendment to Employment Agreement between BrainsWay and Hadar Levy - This Amendment (the “Amendment”) is made as of the date last set forth below by Brain Research and Development Services, Ltd. and/or its affiliates (collectively, “BrainsWay” or “Employer”) and Mr. Hadar Levy (“Executive”), with respect to the Employment Agreement previously entered into on April 13, 2022 (the “Origin |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File No.: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (+972-2 |
|
| March 15, 2023 |
BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights EdgarFiling EXHIBIT 99.1 BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2022 financial results |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| February 14, 2023 |
BWAY / Brainsway Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk2329228.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Brainsway Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 14, 2023 |
BWAY / Brainsway Ltd. / MASTERS CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 d994457513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BrainsWay Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| February 13, 2023 |
Notice to Owners of Ordinary Shares Brainsway Ltd. Exhibit 99.2 Notice to Owners of Ordinary Shares Brainsway Ltd. Proxy Card Owners of record on February 13, 2023 (the “Record Date”) of Ordinary Shares of Brainsway Ltd. (the “Company”) are hereby notified of an upcoming annual general meeting of the Company to be held on Thursday March 20, 2023 in Israel (the “Annual Meeting”). Shareholders registered in the Company's shareholders register in Isr |
|
| February 13, 2023 |
EXHIBIT 99.1 BrainsWay Announces Appointment of Ami Boehm as New Chairman David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board Director BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental he |
|
| February 13, 2023 |
BrainsWay Announces Appointment of Hadar Levy as CEO EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 BrainsWay Announces Appointment of Hadar Levy as CEO BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Hadar Levy, the Company’s Senior |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| February 13, 2023 |
Exhibit 99.1 BRAINSWAY LTD. 19 Hartum Street, Bynet Building, 3rd Floor Har HaHotzvim, Jerusalem 9777518 Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on March 20, 2023 The Annual General Meeting of Shareholders of BrainsWay Ltd. (the “Company”), will be held at the offices of the Company, 19 Hartum Street, Bynet Building, 3rd Fl, Har HaHotzvim, Jerusalem, Israel on March 20, |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February, 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant’s name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Isra |
|
| January 18, 2023 |
SC 13G/A 1 bwaya411823.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Brainsway Ltd. (Name of Issuer) common stock (Title of Class of Securities) 10501L106 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| January 12, 2023 |
BrainsWay Appoints Ami Boehm as Board Member Exhibit 99.1 BrainsWay Appoints Ami Boehm as Board Member BURLINGTON, Mass. and JERUSALEM, January 12, 2023 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that it has appointed Ami Boehm to serve as an independent director on the Company’s Board of Directors. Mr. Boehm has deep experti |
|
| January 10, 2023 |
BrainsWay Resolves Neuronetics Litigation EXHIBIT 99.1 BrainsWay Resolves Neuronetics Litigation BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that it has settled litigation filed by Neuronetics, Inc. (“Neuronetics”) in the District of Delaware. BrainsWay had fil |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| November 30, 2022 |
BWAY / Brainsway Ltd. / Zacut David - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* BrainsWay Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106 (CUSIP Number) November 23, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 30, 2022 |
BWAY / Brainsway Ltd. / Hagai Avner - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* BrainsWay Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106 (CUSIP Number) November 23, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 28, 2022 |
BrainsWay Reports Open Market Stock Purchases by Two Board Members EXHIBIT 99.1 BrainsWay Reports Open Market Stock Purchases by Two Board Members BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that David Zacut, M.D., BrainsWay’s Chairman of the Board of Directors, and Avner Hagai, an ind |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| November 16, 2022 |
EXHIBIT 99.1 BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights Conference call to be held today, November 16, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Nov. 16, 2022 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a world leader in advanced and non-invasive treatment for brain disorders, today reported third quarter |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Isra |
|
| September 14, 2022 |
EXHIBIT 99.1 BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS? Cigna? Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive Disorder BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 14, 2022 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global l |
|
| August 29, 2022 |
EXHIBIT 99.1 BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company’s 9th FDA Clearance BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2022 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| August 10, 2022 |
EXHIBIT 99.1 BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights Revenue Growth of 14% Year-over-Year in Q2 2022 Conference call to be held today, August 10, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 10, 2022 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a world leader in advanced and non-invasive treatment fo |
|
| June 28, 2022 |
EXHIBIT 99.1 BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression The Company?s Groundbreaking Deep TMS? Treatment is Included in Israel?s Health Basket of Essential Medical Services BURLINGTON, Mass. and JERUSALEM, June 28, 2022 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY), (?BrainsWay? or the ?Company?), a world leader in advanced and no |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (A |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| May 11, 2022 |
EXHIBIT 99.1 BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights Revenue Growth of 30% Year-over-Year in Q1 2022 Conference call to be held today, May 11, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 11, 2022 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasive neurostimulation trea |
|
| April 12, 2022 |
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, R. Scott Areglado, certify that: 1. I have reviewed this annual report on Form 20-F of BrainsWay Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| April 12, 2022 |
Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL The following description of the capital stock of BrainsWay is a summary of the rights of our ordinary shares and certain provisions of our articles of association currently in effect. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of association previously filed with the Securities and Exchan |
|
| April 12, 2022 |
Articles of Association of the Registrant, as amended (unofficial English translation). Exhibit 1.1 [UNOFFICIAL TRANSLATION INTO ENGLISH] Amended and Restated Articles of Association of Brainsway Limited [as amended by the shareholders on December 22, 2021] Preamble 1. 1.1. In these Articles of Incorporation, save if the context requires otherwise - ?Man?, ?Person? or ?Persons? Including a corporation ?In Writing? Handwritten, printed, on a typewriter, on a photocopy, telex, fax or i |
|
| April 12, 2022 |
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher von Jako, certify that: 1. I have reviewed this annual report on Form 20-F of BrainsWay Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| April 12, 2022 |
Consent of Kost Forer Gabbay & Kasierer, Member Firm of Ernst & Young Global. Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form F-3 No. 333- 259610) of BrainsWay Ltd. and in the related Prospectus of our report dated April 12, 2022, with respect to the consolidated financial statements of BrainsWay Ltd. included in this Annual Report (Form 20-F) for the year ended December 3 |
|
| April 12, 2022 |
EX-13 9 exh13.htm EXHIBIT 13 Exhibit 13 CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of BrainsWay Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigne |
|
| April 12, 2022 |
Exhibit 4.5 Amendment to BrainsWay Employment Agreement with Christopher R. von Jako, PhD This Amendment (the ?Amendment?) is made as of March 4, 2021 between BrainsWay USA INC., a subsidiary of BrainsWay LTD. (collectively, ?BrainsWay? or the ?Company?) and Christopher R. von Jako, PhD (?Executive?) with respect to the signed Employment Agreement between the aforesaid parties originally entered i |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| April 12, 2022 |
Employment Agreement, dated March 25th, 2021, between BrainsWay Inc. and R. Scott Areglado. Exhibit 4.7 R. SCOTT AREGLADO March 25, 2021 22 Locksley Road Lynnfield, MA 01940 M: (617) 771-2287 E: [email protected] Re: Employment Offer Letter Dear Mr. Areglado, We are very pleased to present to you this offer letter (the ?Employment Offer Letter?) for a position with BrainsWay USA, Inc. (the ?Company? or ?BrainsWay?), as Senior Vice President and Chief Financial Officer for BrainsWay, re |
|
| April 12, 2022 |
Compensation Policy for Executive Officers and Directors, dated December 22, 2021. Exhibit 4.3 BrainsWay Ltd. (The "Company") Compensation Policy (the ?Policy? or ?Compensation Policy?) As adopted by the Company's Shareholders on December 22, 2021. 1. Definitions ?Board? - The Company's board of directors; "Committee" - The Company's compensation committee; "Company" - BrainsWay Ltd.; "Companies Law" - The Companies Law, 1999, Israel; "Director" - The members of the Board of the |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Brainsway Ltd. (Name of Issuer) common stock (Title of Class of Securities) 10501L106 (CUSIP Number) March 29, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| March 9, 2022 |
EXHIBIT 99.1 BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights Revenue Growth of 34% in 2021, with Record Quarterly and Annual Revenues Continued Progress in Expanding FDA Labeling for Deep TMS™ and Increasing Payor Coverage Conference call to be held today, March 9, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 09, 2022 (GLOBE NEWSWIRE) |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| February 14, 2022 |
BWAY / Brainsway Ltd. / MASTERS CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
BWAY / Brainsway Ltd. / RTW INVESTMENTS, LP - BRAINSWAY LTD. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* BrainsWay Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106** (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| February 7, 2022 |
Exhibit 1 [Unofficial Translation] December 12, 2019 Powers of Signature in The Phoenix Holdings Ltd. |
|
| February 7, 2022 |
BWAY / Brainsway Ltd. / Phoenix Holdings Ltd. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Brainsway Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.04 per share (Title of Class of Securities) 10501L106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| January 31, 2022 |
EXHIBIT 99.1 BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS? for the Treatment of OCD Palmetto GBA Covers Medicare Patients in Seven States BURLINGTON, Mass. and JERUSALEM, Jan. 31, 2022 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Brainsway Ltd. (Name of Issuer) common stock (Title of Class of Securities) 10501L106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Brainsway Ltd. (Name of Issuer) common stock (Title of Class of Securities) 10501L106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2021 Commission File No.: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (+97 |
|
| December 9, 2021 |
EXHIBIT 99.1 BrainsWay Announces Publication of Deep TMS? Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects Randomized, Placebo-Controlled, Double-Blind Pilot Study Evaluated Deep TMS Treatment in Reducing Alcohol Consumption and Craving for Adults with Alcohol Use Disorder Study Findings to be Featured Today at Brain Stimulation Conference Symposium BURLINGTON, Mass. and |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| November 17, 2021 |
EXHIBIT 99.1 BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights Revenue Growth of 34% Year-over-Year in Q3 2021 Received Regulatory Clearance for Deep TMS? System for Treatment of Anxious Depression Conference Call to be held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Nov. 17, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November, 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant?s name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Isra |
|
| November 17, 2021 |
Exhibit 99.1 BRAINSWAY LTD. 19 Hartum Street, Bynet Building, 3rd Floor Har HaHotzvim, Jerusalem 9777518 Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 22, 2021 The Annual General Meeting of Shareholders of BrainsWay Ltd. (the ?Company?), will be held at the offices of the Company, 19 Hartum Street, Bynet Building, 3rd Fl, Har HaHotzvim, Jerusalem, Israel on Decembe |
|
| November 17, 2021 |
Exhibit 99.2 17903 Brainsway Ltd VIF Proof 2 Yes No MAIL ? Mark, sign and date your Voting Instruction Form. ? Detach your Voting Instruction Form. ? Return your Voting Instruction Form in the postage - paid envelope provided. Please separate carefully at the perforation and return just this portion in the envelope provided. Please Sign Here Please Date Above Please Sign Here Please Date Above Aut |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| October 6, 2021 |
Brainsway Ltd. 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel Brainsway Ltd. 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel October 6, 2021 By EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 RE: Brainsway Ltd. Registration Statement on Form F-3 Filed September 17, 2021 File No. 333-259610 Ladies and Gentlemen: Pursuant to Rules 460 and 461 of |
|
| September 17, 2021 |
As filed with the Securities and Exchange Commission on September 17, 2021 As filed with the Securities and Exchange Commission on September 17, 2021 Registration No. |
|
| August 18, 2021 |
EXHIBIT 99.1 FDA Clears BrainsWay Deep TMS? System for Decreasing Anxiety Symptoms in Depressed Patients Expanded Depression Indication Further Demonstrates Company?s Leadership Position BURLINGTON, Mass. and JERUSALEM, Aug. 18, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasive neurostimulation treatments for mental |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel |
|
| August 11, 2021 |
EXHIBIT 99.1 BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights Strong Revenue Growth of 45% Year-over-Year in Q2 2021 Gained Meaningful Traction in Reimbursement for Deep TMS? in both OCD and Depression Conference Call to be held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 11, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? o |
|
| June 17, 2021 |
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher von Jako, certify that: 1. I have reviewed this annual report on Form 20-F/A of Brainsway Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light o |
|
| June 17, 2021 |
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, R. Scott Areglado, certify that: I have reviewed this annual report on Form 20-F/A of Brainsway Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR |
|
| June 17, 2021 |
June 17, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2021 Commission File No.:001-35165 BRAINSWAY LTD. (Translation of registrant?s name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Address |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BRAINSWAY LTD. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Ordinary Shares, Par Value NIS 0.04 Per Ordinary Share (Title of Class of Securities) 10501L106 (CUSI |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (A |
|
| June 2, 2021 |
EXHIBIT 99.1 BrainsWay Announces Positive OCD Coverage Policy by Blue Cross Blue Shield? Licensee HCSC HCSC Covers Approximately 17 Million Members Across Five States CRESSKILL, N.J. and JERUSALEM, Israel, June 02, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasive neurostimulation treatments for mental health disord |
|
| June 1, 2021 |
EXHIBIT 99.1 BrainsWay Announces First Draft Proposal for OCD Coverage by a Regional Medicare Administrative Contractor Palmetto GBA, Administrator of Medicare in Seven States, Publishes Draft Local Coverage Determination CRESSKILL, N.J. and JERUSALEM, Israel, June 01, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasi |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (A |
|
| May 24, 2021 |
BrainsWay Updates Line Item in 2021 First Quarter Financial Results EXHIBIT 99.1 BrainsWay Updates Line Item in 2021 First Quarter Financial Results CRESSKILL, N.J. and JERUSALEM, May 24, 2021 - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is reporting an update for a non-cash charge to its unaudited financial results relating to stock-based com |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| May 24, 2021 |
EXHIBIT 99.1 BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS? CRESSKILL, N.J. and JERUSALEM, May 24, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Centene Corporatio |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| May 20, 2021 |
EXHIBIT 99.1 BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights Strong Revenue Growth of 47% Year-over-Year in Q1 2021 Successfully Executed Initial U.S. Controlled Market Release of Deep TMS for Smoking Addiction Strengthened Balance Sheet Through Successful Equity Offering; Ended Q1 2021 with $58.5 Million in Cash Conference Call to be held Today at 8:30 AM ET CRES |
|
| May 5, 2021 |
EXHIBIT 99.1 BrainsWay Announces Appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of R. Scott Areglado |
|
| May 5, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Ad |
|
| May 4, 2021 |
Form of Expiration Notice Email Exhibit (a)(1)(J) FORM OF EXPIRATION NOTICE EMAIL From: BrainsWay Ltd. Re: Expiration of the Exchange Offer The Exchange Offer described in the Offer to Exchange Eligible Options for New Options, dated May 4, 2021 (the ?Offer Documents?), has expired, and no additional Election Forms or Notices of Withdrawal may be submitted. If you are an Eligible Optionholder and delivered a properly completed a |
|
| May 4, 2021 |
Form of Email Notice Regarding Rejection of Options for Exchange Exhibit (a)(1)(I) FORM OF EMAIL NOTICE REGARDING REJECTION OF OPTIONS FOR EXCHANGE From: BrainsWay Ltd. |
|
| May 4, 2021 |
Notice of Withdrawal of Election Form Exhibit (a)(1)(D) INSTRUCTIONS TO NOTICE OF WITHDRAWAL OF ELECTION FORM If you previously elected to accept the offer by BrainsWay Ltd. |
|
| May 4, 2021 |
Exhibit (a)(1)(A) BRAINSWAY LTD. 19 Hartum Street, Bynet Building, 3rd Floor, Har HaHotzvim, Jerusalem, 9777518, Israel OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS May 4, 2021 BRAINSWAY LTD. SUMMARY TERM SHEET ? OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS This offer and withdrawal rights will expire at 5:00 p.m., Eastern Time, on Wednesday, June 2, 2021 unless extended By th |
|
| May 4, 2021 |
Form of Email Confirming Receipt of Notice of Withdrawal of Election Form Exhibit (a)(1)(F) FORM OF EMAIL CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION FORM From: BrainsWay Ltd. |
|
| May 4, 2021 |
Form of Reminder Email to Eligible Optionholders Regarding the Expiration of the Exchange Offer Exhibit (a)(1)(G) FORM OF REMINDER EMAIL TO ELIGIBLE OPTIONHOLDERS REGARDING THE EXPIRATION OF THE EXCHANGE OFFER From: BrainsWay Ltd. |
|
| May 4, 2021 |
BrainsWay Form of Award Agreement Exhibit (d)(2) NOTICE OF OPTION GRANT You have been granted the following options (the ?Options?) to purchase Ordinary Shares par value NIS 0. |
|
| May 4, 2021 |
Form of Announcement Email to Eligible Optionholders Exhibit (a)(1)(B) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE OPTIONHOLDERS Subject: BrainsWay Ltd. |
|
| May 4, 2021 |
SC TO-I 1 sctoi042721.htm SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BRAINSWAY LTD. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Ordinary Shares, Par Value NIS 0.04 Per Ordinary Share (Title of Class of Securities) 1 |
|
| May 4, 2021 |
Form of Email to Eligible Optionholders Confirming Acceptance of Eligible Options Exhibit (a)(1)(H) FORM OF EMAIL TO ELIGIBLE OPTIONHOLDERS CONFIRMING ACCEPTANCE OF ELIGIBLE OPTIONS From: BrainsWay Ltd. |
|
| May 4, 2021 |
Form of Email Confirming Receipt of Election Form Exhibit (a)(1)(E) FORM OF EMAIL CONFIRMING RECEIPT OF ELECTION FORM From: BrainsWay Ltd. |
|
| May 4, 2021 |
Exhibit (a)(1)(C) BRAINSWAY LTD. 19 HARTUM STREET, BYNET BUILDING, 3RD FLOOR, Har HaHotzvim JERUSALEM, 9777518, ISRAEL OPTION EXCHANGE ? ELECTION FORM THIS OFFER AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON WEDNESDAY, JUNE 2, 2021, UNLESS EXTENDED Before completing and signing this Election Form, we encourage you to read the documents that make up this tender offer, includ |
|
| April 26, 2021 |
EXHIBIT 99.1 BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder Shorter Protocol Further Expands Access to Care CRESSKILL, N.J. and JERUSALEM, April 26, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasive neurostimulation treatments for mental health disorder |
|
| April 26, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| April 19, 2021 |
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Hadar Levy, certify that: I have reviewed this annual report on Form 20-F of Brainsway Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumsta |
|
| April 19, 2021 |
Articles of Association of the Registrant, as amended (unofficial English translation). Exhibit 1.1 [UNOFFICIAL TRANSLATION INTO ENGLISH] Amended and Restated Articles of Association of Brainsway Limited Preamble 1. 1.1. In these Articles of Incorporation, save if the context requires otherwise - ?Man?, ?Person? or ?Persons? Including a corporation ?In Writing? Handwritten, printed, on a typewriter, on a photocopy, telex, fax or in any other manner which is readable. ?Registered Shar |
|
| April 19, 2021 |
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher von Jako, certify that: 1. I have reviewed this annual report on Form 20-F of Brainsway Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| April 19, 2021 |
Exhibit 4.1 Brainsway Ltd. Amended and restated 2019 Share Incentive Plan Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1 Purpose. The purpose of this Amended and Restated 2019 Share Incentive Plan (as amended, this ?Plan?) is to afford an incentive to Service Providers of Brainsway Ltd., an Isr |
|
| April 19, 2021 |
Consent of Kost Forer Gabbay & Kasierer, Member Firm of Ernst & Young Global. Exhibit 15.1 Kost Forer Gabbay & Kasierer 144 Menachem Begin Road, Building A Tel-Aviv 6492102, Israel Tel: +972-3-6232525 Fax: +972-3-5622555 ey.com CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-230979) of Brainsway Ltd. of our report dated April 19, 2021 with respect to the consolida |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| April 19, 2021 |
Exhibit 13 CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Brainsway Ltd. |
|
| March 24, 2021 |
EXHIBIT 99.1 BrainsWay Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET CRESSKILL, N.J. and JERUSALEM, March 24, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in advanced noninvasive neurostimulation treatments for mental health dis |
|
| March 24, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| March 4, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| March 1, 2021 |
EXHIBIT 99.1 BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full Exercise of Underwriters? Option to Purchase Additional American Depositary Shares CRESSKILL, N.J. and JERUSALEM, March 01, 2021 (GLOBE NEWSWIRE) - BrainsWay Ltd. (NASDAQ & TASE: BWAY) (?BrainsWay? or the ?Company?), a global leader in the advanced noninvasive tr |
|
| March 1, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel ( |
|
| February 25, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-35165 BRAINSWAY LTD. (Translation of registrant's name into English) 19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israe |
|
| February 25, 2021 |
Underwriting Agreement, dated February 23, 2021, between Registrant and Oppenheimer & Co. Inc. Exhibit 1.1 Execution Version BRAINSWAY LTD. 4,622,000 American Depositary Shares Representing an Aggregate of 9,244,000 Ordinary Shares (par value NIS 0.04 per share) Underwriting Agreement February 23, 2021 Oppenheimer & Co. Inc. As Representative of the several Underwriters listed in Schedule A hereto c/o Oppenheimer & Co. Inc. 85 Broad Street New York, NY 10004 Ladies and Gentlemen: Brainsway |
|
| February 24, 2021 |
4,622,000 American Depositary Shares representing 9,244,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-248601 PROSPECTUS SUPPLEMENT (To Prospectus dated October 16, 2020) 4,622,000 American Depositary Shares representing 9,244,000 Ordinary Shares We are offering 4,622,000 American Depositary Shares (“ADSs”) pursuant to this prospectus supplement and accompanying prospectus. Each ADS represents two of our Ordinary Shares, par value NIS0.04 per sh |
